IS

iSpecimen Inc.

  • CIK: 0001558569
  • EIN: 27-0480143
  • Business address: 450 BEDFORD STREET, SUITE 1010, LEXINGTON, Massachusetts, 02420

Information

  • Mailing address
    450 BEDFORD STREET, SUITE 1010, LEXINGTON, Delaware, 02420
  • Phone
    781-301-6700
  • State location
    Massachusetts
  • State of incorporation
    Delaware
  • Fiscal year end
    December 31
  • SIC
    8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
  • Filings
    N/A

About iSpecimen Inc.

iSpecimen Inc. (CIK: 0001558569) is an American company incorporated in the state of Massachusetts. Head office is located at 450 BEDFORD STREET, SUITE 1010, LEXINGTON, Massachusetts, 02420. Work in the industry 8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH. iSpecimen Inc. is a public company and trade via Over-The-Counter (OTC).

Ownership

Owner Filings Transaction Date Type of Owner
Basile Joseph J. 0001954843 Nov-28-2022 director
Brooks John L 0001343930 Jun-16-2021 director
Gullans Steven R. Ph.D. 0001571997 Jun-16-2021 director
OBF Investments, LLC 0001857012 Jun-16-2021 10 percent owner
Ross Andrew L. 0001857013 Jun-16-2021 director, 10 percent owner
Lawrence Margaret H. 0001857015 Jun-16-2021 director
Scholl George H. 0001857026 Jun-16-2021 director
Ianelli Christopher 0001857027 Jun-16-2021 director, officer: CEO, President
Curley Tracy 0001857028 Jun-16-2021 officer: Chief Financial Officer
Mullan Jill 0001857039 Jun-16-2021 director, officer: COO, Secretary, Treasurer
Bielak Benjamin 0001857054 Jun-16-2021 officer: Chief Information Officer

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by iSpecimen Inc.

Filings Format Description Filed/Effective File/Film Number
S-1/A Document

Amendment to General form of registration statement for all companies including face-amount certificate companies

Acc-no: 0001213900-25-096648 (33 Act) Size: KB		 Oct-06-2025

333-289725

251377721
PRER14A Document

Preliminary revised proxy soliciting materials

Acc-no: 0001213900-25-095450 (34 Act) Size: KB		 Oct-02-2025

001-40501

251369702
S-1/A Document

Amendment to General form of registration statement for all companies including face-amount certificate companies

Acc-no: 0001213900-25-085541 (33 Act) Size: KB		 Sep-08-2025

333-289725

251300455
PRER14A Document

Preliminary revised proxy soliciting materials

Acc-no: 0001213900-25-085188 (34 Act) Size: KB		 Sep-08-2025

001-40501

251297717
8-K Document

Current report filing

Acc-no: 0001213900-25-084497 (34 Act) Size: KB		 Sep-04-2025

001-40501

251293391
S-1/A Document

Amendment to General form of registration statement for all companies including face-amount certificate companies

Acc-no: 0001213900-25-080408 (33 Act) Size: KB		 Aug-25-2025

333-289725

251251908
8-K Document

Current report filing

Acc-no: 0001213900-25-079167 (34 Act) Size: KB		 Aug-21-2025

001-40501

251238416
S-1 Document

General form of registration statement for all companies including face-amount certificate companies

Acc-no: 0001213900-25-078951 (33 Act) Size: KB		 Aug-20-2025

333-289725

251236657
10-Q Document

Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001213900-25-076629 (34 Act) Size: KB		 Aug-14-2025

001-40501

251218817
PRE 14A Document

Preliminary proxy statement not related to a contested matter or merger/acquisition

Acc-no: 0001213900-25-075711 (34 Act) Size: KB		 Aug-13-2025

001-40501

251212140
8-K Document

Current report filing

Acc-no: 0001213900-25-073069 (34 Act) Size: KB		 Aug-07-2025

001-40501

251193886
D Document Acc-no: 0001213900-25-072548 (33 Act) Size: KB Aug-06-2025

021-553895

251189446
8-K Document

Current report filing

Acc-no: 0001213900-25-072070 (34 Act) Size: KB		 Aug-05-2025

001-40501

251184891
8-K Document

Current report filing

Acc-no: 0001213900-25-067772 (34 Act) Size: KB		 Jul-25-2025

001-40501

251152038
424B4 Document

Prospectus filed pursuant to Rule 424(b)(4)

Acc-no: 0001213900-25-067485 (33 Act) Size: KB		 Jul-25-2025

333-286958

251149003
EFFECT Document Acc-no: 9999999995-25-002324 (33 Act) Size: KB Jul-23-2025

333-286958

251144381
CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001213900-25-066107 ( Act) Size: KB		 Jul-21-2025

CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001213900-25-066101 ( Act) Size: KB		 Jul-21-2025

CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001213900-25-063642 ( Act) Size: KB		 Jul-14-2025

CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001213900-25-063639 ( Act) Size: KB		 Jul-14-2025

Recent 20 filings. View all iSpecimen Inc. filings

Reviews

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Frequently Asked Questions

Tags:

  • iSpecimen Inc. overview
  • iSpecimen Inc. job
  • iSpecimen Inc. stock
  • iSpecimen Inc. ownership
  • iSpecimen Inc. CEO
  • iSpecimen Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

OTSAW Ltd
Update: Jun 10, 2025
Zymergen Inc.
Update: Aug 26, 2022
XXSYS TECHNOLOGIES INC /CA
Update: Aug 25, 2022
WHISTLER INC
Update: Aug 25, 2022
WCG Clinical, Inc.
Update: Aug 25, 2022
Viventia Biotech Inc.
Update: Aug 24, 2022

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 4022 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 2899 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 1651 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 3170 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 4988 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 3995 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 4311 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 2647 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 2802 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by